

Curriculum Vitae

Dimitris Kardassis, PhD

Professor of Biochemistry

University of Crete Medical School

Tel. +30-2810-321889

e-mail : kardasis@imbb.forth.gr; kardasis@uoc.gr

Undergraduate education

1981-1985

B. Sc. in Biology, Department of Biology, Aristotelian University of Thessaloniki, Thessaloniki, Greece

Graduate education

1986-1991

Ph.D. in Biochemistry, Department of Biochemistry, Boston University Medical School, Boston, MA, USA

Postdoctoral education

1991-1992

Postdoctoral fellow, Section of Molecular Genetics, Whittaker Cardiovascular Institute, Boston University Medical School, Boston, MA, USA.

Academic Positions

1993-1996

Research Associate, University of Crete Medical School

1996-1998

Adjunct Assistant Professor of Biochemistry, University of Crete Medical School

1998-

Assistant Professor of Biochemistry, University of Crete Medical School

1999-

Affiliated Member, Division of Development and Gene Expression, Institute of Molecular Biology and Biotechnology

2004-2008

Associate Professor of Biochemistry, University of Crete Medical School

2009-

Professor of Biochemistry, University of Crete Medical School

Fellowships

1981-1985

Fellowship from the Foundation for National Fellowships (IKY)

1986-1991

Research Assistantship, Section of Molecular Genetics, Cardiovascular Institute, Boston University Medical Center

1991-1992

Postdoctoral Fellowship, Section of Molecular Genetics, Cardiovascular Institute, Boston University Medical Center

1994

EMBO Short Term Fellowship

Awards/Distinctions

1999

Young Investigator Award, European Atherosclerosis Society

2009

Chairman of the Department of Basic Sciences, University of Crete Medical School

2010

Election as Chair of COST Action BM0904 "HDL: from biological understanding to clinical exploitation"

2013

Member of the Organizing Committee of the European Lipoprotein Club (2013-2017)

2012

Director of the Graduate Program "The Molecular Basis of Human Diseases" of the University of Crete Medical School

Teaching duties

Undergraduate courses

1993-

Teaching in the following courses of the Department of Medicine of the University of Crete:

- a) Biochemistry I (2nd semester): 24 hours of lectures and 20 hours of tutoring
 - b) Biochemistry II (3rd semester): 6 hours of lectures
 - c) Molecular Medicine (5th semester): 6 - 8 hours of lectures and 10 hours of student presentations
- Total teaching hours:** 60 - 70 hours/year

Graduate courses

a) Graduate courses offered by the Graduate Program in Molecular Biology and Biomedicine (Departments of Medicine and Biology of the University of Crete) (<http://www.imbb.forth.gr/mbb/>)

1998-2007

- Coordination of the graduate course “Molecular Biology of the gene”
- Teaching in the graduate course “Molecular Biology of the cell”
- Teaching in the graduate course “Multidisciplinary approach to understand and cure human diseases”
- Coordination of the graduate course “Introduction to Research Methods”
- Teaching in the graduate course: “Molecular Biology of Cancer”
- Coordination of the graduate course “Molecular Organization of Life”
- Teaching in the graduate course “Cellular Organization of Life”
- Teaching in the graduate course “Organization and processing of biological information”

b) Graduate courses offered by the Graduate Program “The molecular basis of human diseases” (Department of Medicine of the University of Crete) (<http://www.grad-mbhd-uoc.gr>)

2003-

- Coordinator of the graduate course “Introduction to molecular medicine and basic principles of research methodology”
- Teaching in the graduate course “A multidisciplinary approach to understand the molecular basis of human diseases”
- Teaching in the graduate course “Cancer”

Funding

1999-2002 Program “Human Frontiers (HFSP)” funded by HFSO: Coordinator: Michnick S. Partners: **D. Kardassis**, A. Moustakas, K. Luo. “TGF- β : From the cell surface to the nucleus”, US\$ 120,000

1999-2001 Program “PENED-99” funded by the Greek Ministry of Education: Coordinator: **D. Kardassis**. “Transcriptional mechanisms and signaling pathways that control the expression of the human apolipoprotein genes“, 147.000 €

2002-2005 Program “PENED-2001” funded by the Greek Ministry of Education: Coordinator: **D. Kardassis**. “Functions and regulation of the apolipoprotein E gene: Applications to the treatment of cardiovascular Disease and Alzheimer’s Disease”, 235.000 €

2004-2006 “Collaboration between Greece and the USA” program funded by the Greek Ministry of Research and Technology” Coordinator: **D. Kardassis (Greece)** Partner: V. Zannis (USA). “ A genomics approach to elucidate the role of the lipid transporter ABCA1 in cholesterol homeostasis ”, 60.000 €.

2006-2008 Program “PENED-2003” funded by the Greek Ministry of Research and Technology: Coordinator: **D. Kardassis**. “Transcriptional regulation of genes involved in the biogenesis and catabolism of HDL: New approaches to increase plasma HDL levels”, 210.000 €

- 2006-2008 Program “PENED-2003” funded by the Greek Ministry of Research and Technology: Coordinator: C. Sournaras. **Partner: D. Kardassis** “The role of Rho small GTPases in the genomic and non-genomic cellular responses to cytokines”, 180.000 €
- 2005-2007 Program “PYTHAGORAS II” funded by the Greek Ministry of Education: Coordinator: **D. Kardassis**. “Mechanisms of gene regulation by the Transforming Growth Factor β and the Smad proteins”, 50.000 €
- 2006-2007 “Collaboration between Greece and Romania” program funded by the Greek Ministry of Research and Technology” Coordinator: **D. Kardassis (Greece)** Partner: A. Gafencu (Romania). “Regulation of the expresion of the human apolipoprotein E gene in macrophages and the brain: new approaches for the treatment of dyslipidemias and Alzheimer’s Disease ”, 14.000 €.
- 2007-2009 Sixth Framework Program-Health-STREP. Funded by EU. Coordinator: **A. von Eckardstein (Switzerland)** Partners: V. Zannis, **D. Kardassis (Greece)**. “Functional genomics of inborn errors and therapeutic interventions in high density lipoprotein (HDL) metabolism”. Budget for the team: 420.000 €.
- 2011-2014 Program “SYNERGASIA 09” funded by the General Secretariat for Research and Technology of Hellas “Targeted strategies for new therapies of Cardiovascular and Inflammatory Diseases based on the atheroprotective functions of HDL”. **Coordinator: D. Kardassis**. Patners: A. Chroni (Demokritos), D. Boumpas (Ucrete), Abbott Hellas 500.000 €
- 2010-2013 Program “HRAKLEITOS II” funded by the Greek Ministry of Education. **Coordinator: D. Kardassis**. PhD candidate: P. Fotakis. “Proteins that regulated HDL levels and functions”. 45.000 €
- 2010-2014 COST Action BM0904: “HDL- From Biological Understanding to Clinical Exploitation”. Funded by EU/ESF. **Chair: D. Kardassis (Greece)**. Participants from 15 European countries. 100.000 €year
- 2012-2015 Research program THALIS funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “Structure/function, regulation and genetic variation of High Density Lipoproteins: Novel biomarkers and therapies for patients with Coronary Artery Disease”. **Coordinator: D. Kardassis**. Total budget: 520.000 €. Budget for the team: 200.000 €.
- 2012-2015 Research program THALIS funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. Title: “Cell cycle variations: comparing the stem cell and cancer cell life cycles”. Coordinator: Z. Lygerou. **Coordinator of the University of Crete team: D. Kardassis**. Total budget: 520.000 Euros. Budget for the team: 160.000 €
- 2012-2014 Cooperation between Greece and Romania in Science and Technology funded by the Greek Ministry of Education, Religious Affairs and Lifelong Learning. **Coordinator: D. Kardassis (Greece)**. Romanian parner: Prof. M. Simionescu (Bucharest). Title: Prospects fot novel therapies of Cardiovascular Diseases that are based on the transcriptional regulation of the apoE gene. 15.000 €.
- 2013-2017 “RESOLVE: A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol”. Funded by EU FP7-HEALTH-2012-INNOVATION-1 program. Integrated

Publications

1. Zannis VI, MM Hussain, M Hadzopoulou-Cladaras, A Kouvatsi, **D Kardassis**, C Cladaras. (1988). Molecular biology of human apolipoprotein B and related diseases. *Adv. Exp. Med. Biol.* 243:107-121.
2. **Kardassis D**, M Hadzopoulou-Cladaras, D Ramji, R Cortese, VI Zannis, C Cladaras. (1990). Characterization of the promoter elements required for hepatic and intestinal transcription of the human apoB gene: Definition of the binding site of a tissue-specific transcriptional factor. *Mol. Cell Biol.* 10:2653-2658.
3. **Kardassis D**, VI Zannis, C Cladaras. (1990). Purification and characterization of the nuclear factor BA1: A transcriptional activator of the human apoB gene. *J. Biol. Chem.* 265:21733-21740.
4. Zannis VI, **D Kardassis**, K Ogami, M Hadzopoulou-Cladaras, C Cladaras. (1991). Transcriptional regulation of the human apolipoprotein genes. *Adv. Exp. Med. Biol.* 285,1-23.
5. Ogami K, **D Kardassis**, C Cladaras, VI Zannis. (1991). Purification and characterization of a heat stable nuclear factor CIIB1 involved in the regulation of the human apoCIII gene. *J. Biol. Chem.* 266:9640-9646.
6. Zannis VI, **D Kardassis**, P Cardot, M Hadzopoulou-Cladaras, EE Zanni, C Cladaras. (1992). Molecular biology of the human apolipoprotein genes: Gene regulation and structure/function relationship. *Curr. Opin. Lipid.* 3:96-113.
7. **Kardassis D**, VI Zannis, C Cladaras. (1992). Organization of the regulatory elements and nuclear activities participating in the transcriptional activation of the apolipoprotein B gene. *J. Biol. Chem.* 267:2622-2632.
8. Ladias AA, M Hadzopoulou-Cladaras, **D Kardassis**, P Cardot, J Cheng, VI Zannis, C Cladaras. (1992). Transcriptional regulation of human apolipoprotein genes apoB, apoCIII and apoAII by members of the steroid hormone receptor superfamily: HNF-4, ARP-1, EAR-2, and EAR-3. *J. Biol. Chem.* 267:15849-15860.
9. Cardot, Chambaz J, **Kardassis D**, Cladaras C and Zannis V. I. (1993) Factors participating in the liver-specific expression of the human apolipoprotein A-II gene and their significance for transcription. *Biochemistry* 32: 9080-9093.
10. **Kardassis D**, Laccotrippe, M., Talianidis, I. and Zannis, V. (1996) Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. *Hypertension* 27: 980-1008.
11. **Kardassis, D.**, Tzameli, I., Talianidis, I. and Zannis V. (1997) The distal apoC-III regulatory elements F to J act as a general modular enhancer for proximal promoters containing hormone response elements. *Arteriosclerosis, Thrombosis & Vascular Biology.* 17:222-232.
12. Vorgia P., Zannis V. and **Kardassis D.** (1998) A short proximal promoter and Hepatic Control Region-1 contribute to the tissue-specific expression of the apoC-II gene in vitro. *J. Biol. Chem.* 273:4188-4196.
13. Moustakas, A. and **Kardassis, D.** (1998) Activation of the human p21/WAF1/Cip1 gene promoter in hepatic cells by interactions between Sp1 and Smad family members. *Proc Natl Acad Sci U S A.* 95(12):6733-8.
14. **Kardassis, D.**, Sacharidou, E. and Zannis, V. (1998) Activation of the human apolipoprotein C-II promoter by orphan and ligand-dependent nuclear receptors: The regulatory element CII-C is a functional Thyroid Hormone responsive Element (TRE) *J Biol Chem.* 273(28):17810-6.
15. Hadzopoulou-Cladaras, M., Lavrentiadou, S., Zannis, V. and **Kardassis, D.** (1998) Transactivation of the human apoC-III promoter by Activating Transcription Factor-2 (ATF-2) and repression by members of the c-jun family. *Biochemistry.* 37:14078-87.

16. Lavrentiadou, S., Hadzopoulou-Cladaras, M., **Kardassis, D.** and Zannis, V. (1999) Binding specificity and modulation of the apoC-III promoter activity by heterodimers of ligand-dependent nuclear receptors. *Biochemistry*. 38(3):964-75.
17. Ribeiro A, Pastier D, **Kardassis D**, Chambaz J, Cardot P (1999) Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. *J Biol Chem* 274(3):1216-25.
18. Tsapara A, **Kardassis D**, Moustakas A, Gravanis A, and Stournaras C (1999) Expression and characterization of Cys374 mutated human beta-actin in two different mammalian cell lines: impaired microfilament organization and stability. *FEBS Lett* 455(1-2):117-22.
19. **Kardassis, D**, Papakosta, P, Pardali, K. and Moustakas, A. (1999) c-Jun transactivates the promoter of the human p21/WAF-1 gene by acting as a superactivator of the ubiquitous transcription factor Sp1. *J. Biol. Chem.* 274:29572-29581.
20. Pardali, K., Kurisaki, A., Moren A., ten Dijke, P., **Kardassis, D.** and Moustakas, A. (2000) Role of Smad proteins and transcription factor Sp1 in p21/WAF1/Cip1 regulation by Transforming Growth Factor β . *J Biol Chem.* 275(38):29244-56.
21. **Kardassis, D.**, Pardali, K. and Zannis, V. (2000) SMAD proteins transactivate the human apoC-III promoter by interacting physically and functionally with Hepatocyte Nuclear Factor 4. *J. Biol. Chem.* 275(52):41405-14.
22. Koutsodontis G, Tentis I, Papakosta P, Moustakas A, **Kardassis D.** (2001) Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. *J Biol Chem.* 276(31):29116-25.
23. Zannis VI, Kan HY, Kritis A, Zanni EE, **Kardassis D.** (2001) Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. *Curr Opin Lipidol* 12(2):181-207.
24. Zannis VI, Kan HY, Kritis A, Zanni E, **Kardassis D.** (2001) Transcriptional regulation of the human apolipoprotein genes. *Front Biosci* 1;6:D456-504.
25. Prokova V, Mosialos G, **Kardassis D.** (2002) Inhibition of transforming growth factor β signaling and Smad-dependent activation of transcription by the latent membrane protein 1 of Epstein Barr Virus. *J Biol Chem.* 277(11):9342-50.
26. **Kardassis, D.**, Flavey E., Tsantili, P., Hadzopoulou-Cladaras, M. and Zannis, V. I. (2002) Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein C-III promoter. *Biochemistry*. 41(4):1217-28.
27. Koutsodontis, G., Moustakas, A. and **Kardassis, D.** (2002) The Role of Sp1 Family Members, the Proximal GC-Rich Motifs, and the Upstream Enhancer Region in the Regulation of the Human Cell Cycle Inhibitor p21(WAF-1/Cip1) Gene Promoter. *Biochemistry*. 41(42):12771-12784.
28. Chou, C., Prokova, V., Shiraishi, K., Valcourt, U., Moustakas, A., Hadzopoulou-Cladaras, M., Zannis, V and **Kardassis D.** (2003) Smad proteins co-activate hepatocyte nuclear factor 4 by interacting with multiple domains and enhance hepatic gene transcription. *Mol Biol Cell* 14, 1279-1294.
29. **Kardassis, D.**, Roussou, A., Papacosta, P., Boulias, K., Talianidis, I., and Zannis, V.I. (2003) Synergism between nuclear receptors bound to specific sites of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene induction by bile acids and retinoids. *Biochem J.* 372, 291-304.
30. Hatzivassiliou, E, Koukos, G., Ribeiro, A., Zannis, V.I. and **Kardassis, D.** (2003) Functional specificity of two hormone response elements present on the human apoA-II promoter that bind RXRa/T3Rb heterodimers for retinoids and thyroids: synergistic interactions between T3Rb and the ubiquitous transcription factor USF2a. *Biochemical J.* 376, 423-31.
31. Zannis, V., Liu, T., Zanni, E., Kan, H. and **Kardassis, D.** (2003) Regulatory gene mutations affecting apolipoprotein gene expression: functions and regulatory behavior of known genes

- may guide future pharmacogenomic approaches to therapy. *Clin Chem Lab Med.* 41(4):411-24.
32. Zannis, V., Chroni, A., Kypreos, K., Kan, HY., Cesar, TB., Zanni, EE. And **Kardassis, D.** (2004) Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. *Curr. Op. Lipid.* 15(2):151-66.
 33. Koutsodontis, G. and **Kardassis, D.** (2004) Inhibition of p53-mediated transcriptional responses by mithramycin A. *Oncogene.* 23, 9190-200.
 34. Koutsodontis G, Vasilaki E, Chou WC, Papakosta, P. and **Kardassis D.** (2005) Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. *Biochem J.* 389, 443-55.
 35. Prokova, V, Mavridou, S, Papakosta, P. and **Kardassis, D.** (2005) Characterization of a novel transcriptionally active domain in the transforming growth factor beta-regulated Smad3 protein. *Nucleic Acids Res.* 33, 3708-21.
 36. Nikolaidou-Neokosmidou V, Zannis VI and **Kardassis D.** (2006) Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. *Biochem J.* 398, 439-50.
 37. Drosatos K, Sanoudou D, Kypreos KE, **Kardassis D** and Zannis VI. (2007) A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. *J Biol Chem.* 282, 19556-64.
 38. Koukos G, Chroni A, Duka A, **Kardassis D,** and Zannis VI. (2007) Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. *Biochem J.* 406, 167-74.
 39. Gafencu AV, Robciuc MR, Fuior E, Zannis VI, **Kardassis D,** and Simionescu M. (2007) Inflammatory signaling pathways regulating ApoE gene expression in macrophages. *J Biol Chem.* 282, 21776-85.
 40. Koukos G, Chroni A, Duka A, **Kardassis D,** and Zannis VI. (2007) LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. *Biochemistry.* 46, 10713-21.
 41. Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, **Kardassis D,** Gold SJ, and Zachariou V. RGS9-2 is a negative modulator of mu-opioid receptor function. *J Neurochem.* 103, 617-25.
 42. Thymiakou E, Zannis VI, and **Kardassis D.** (2007) Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoids. *Biochemistry.* 46, 11473-83.
 43. Prokova V, Mavridou S, Papakosta P, Petratos K, and **Kardassis D.** (2007) Novel mutations in Smad proteins that inhibit signaling by the transforming growth factor beta in mammalian cells. *Biochemistry.* 46, 13775-86.
 44. Stavroulaki M, **Kardassis D,** Chatzaki E, Sakellaris G, Lindschau C, Haller H, Tosca A, and Krasagakis K. (2008) Exposure of normal human melanocytes to a tumor promoting phorbol ester reverses growth suppression by transforming growth factor beta. *J Cell Physiol.* 214, 363-70.
 45. Minoo P, Hu L, Zhu N, Borok Z, Bellusci S, Groffen J, **Kardassis D,** and Li C. (2008) SMAD3 prevents binding of NKX2.1 and FOXA1 to the SpB promoter through its MH1 and MH2 domains. *Nucleic Acids Res.* 36, 179-88.
 46. Vardouli L, Vasilaki E, Papadimitriou E, **Kardassis D** and Stournaras C (2008) A novel mechanism of TGF β -induced actin reorganization mediated by Smad proteins and Rho GTPases. *FEBS J.* 275(16):4074-87.
 47. Moschonas A, Kouraki M, Knox P, Thymiakou E, **Kardassis D** and Eliopoulos AG (2008) CD40 ligation induces antigen transporter and immunoproteasome gene expression in

- carcinomas via the coordinated action of NF- κ B and of NF- κ B mediated *de novo* synthesis of IRF-1. *Mol Cell Biol.* 28(20):6208-22.
48. Akoumianaki, A., Georgatos, S., **Kardassis, D.** and Theodoropoulos, P. (2009) Nucleocytoplasmic shuttling of soluble tubulin in mammalian cells. *J Cell Sci* 122, 1111-1118.
 49. **Kardassis D,** Murphy C, Fotsis T, Moustakas A, Stournaras C. (2009) Control of transforming growth factor beta signal transduction by small GTPases. *FEBS J.* 2009 Jun;276(11):2947-65.
 50. Vasilaki, E., Siderakis, M., Papakosta, P., Skourti-Stathaki, K. Mavridou, S. and **Kardassis, D.** (2009) Novel regulation of Smad3 oligomerization and DNA binding by its linker domain. *Biochemistry.*48(35):8366-78.
 51. Bertias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, Kritikos H, Sidiropoulos P, Tzardi M, **Kardassis D,** Mamalaki C, Boumpas DT. (2009) Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. *Arthritis Rheum.* 60(1):207-18.
 52. Vasilaki E, Papadimitriou E, Tajadura V, Ridley AJ, Stournaras C and **Kardassis D.** (2010) Transcriptional regulation of the small GTPase RhoB gene by TGF{beta}-induced signaling pathways. *FASEB J.* 24(3):891-905.
 53. Mavridou S, Venihaki M, Rassouli O, Tsatsanis C, and **Kardassis D.** (2010) Feedback inhibition of human scavenger receptor class B type I gene expression by glucocorticoid in adrenal and ovarian cells. *Endocrinology* 151(7):3214-24.
 54. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, **Kardassis D,** Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. (2010) Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. *Cancer Res.* 70(12):4949-60.
 55. Mosialou I, Zannis VI, and **Kardassis D.** (2010) Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. *J Biol Chem.* 285(40):30719-30.
 56. Goulielmos GN, Petraki E, Vassou D, Eliopoulos E, Iliopoulos D, Sidiropoulos P, Aksentijevich I, **Kardassis D,** and Boumpas DT. (2010) The role of the pro-apoptotic protein Siva in the pathogenesis of Familial Mediterranean fever: A structural and functional analysis. *Biochem Biophys Res Commun.*402(1):141-6
 57. Ohnsorg PM, Rohrer L, Perisa D, Kateifides A, Chroni A, **Kardassis D,** Zannis VI, and von Eckardstein A. (2011) Carboxyl Terminus of Apolipoprotein A-I (ApoA-I) Is Necessary for the Transport of Lipid-free ApoA-I but Not Prelipidated ApoA-I Particles through Aortic Endothelial Cells. *J Biol Chem.* 286(10):7744-54
 58. Trusca GV, Fuor EV, Florea IC, **Kardassis D,** Simionescu M, and Gafencu AV. (2011) Macrophage-specific upregulation of apolipoprotein E gene expression by STAT1 is achieved via long-range genomic interactions. *J Biol Chem.* [Epub ahead of print]
 59. Mosialou I, Krasagakis K, and **Kardassis D.** (2011) Opposite regulation of the human apolipoprotein M gene by oHepatocyte Nuclear Factor 1 and Jun transcription factors. *J Biol Chem.* 13;286(19):17259-69.
 60. Stender S, Frikke-Schmidt R, Anestis A, **Kardassis D,** Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. (2011) Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population. *Arterioscler Thromb Vasc Biol.* 31(12):2990-6.
 61. Kateifides AK, Gorshkova IN, Duka A, Chroni A, **Kardassis D,** Zannis VI. (2011) Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL. *J Lipid Res.* 52(7):1363-72.
 62. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, **Kardassis D,** Nielsen LB, Andersen CB, Køber L, Johnsen AH, Grande P, Zannis VI, Tybjaerg-Hansen A. (2011)

- Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. *J Intern Med.* 270(2):136-46
63. Wojciak-Stothard B, Zhao L, Oliver E, Dubois O, Wu Y, **Kardassis D**, Vasilaki E, Huang M, Mitchell JA, Louise H, Prendergast GC, Wilkins MR. (2012) Role of RhoB in the Regulation of Pulmonary Endothelial and Smooth Muscle Cell Responses to Hypoxia. *Circ Res.* 110(11):1423-34.
 64. Schou J, Frikke-Schmidt R, **Kardassis D**, Thymiakou E, Nordestgaard BG, Jensen G, Grande P, Tybjærg-Hansen A. (2012) Genetic variation in ABCG1 and risk of myocardial infarction and ischemic heart disease. *Arterioscler Thromb Vasc Biol.* 32(2):506-15.
 65. Papadimitriou E, Vasilaki E, Vorvis C, Iliopoulos D, Moustakas A, **Kardassis D**, Stournaras C. (2012) Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF- β and miR-24: role in epithelial-to-mesenchymal transition. *Oncogene.* 31(23):2862-75.
 66. Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, **Kardassis D**, Zannis VI. (2012) ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. *J Lipid Res.* 54(1):107-15.
 67. Trusca VG, Florea IC, **Kardassis D**, Gafencu AV. STAT1 interacts with RXR α to upregulate ApoCII gene expression in macrophages. *PLoS One.* 2012;7(7):e40463.
 68. Stagakis I, Bertsiaris G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, **Kardassis D**, Boumpas DT, Sidiropoulos PI. (2012) Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. *Arthritis Res Ther.* 14(3):R141.
 69. Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, **Kardassis D**, Zannis VI. (2013) ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. *J Lipid Res.* 54(1):107-15.
 70. Papadakis G, Tsortos A, Kordas A, Tiniakou I, Morou E, Vontas J, **Kardassis D**, Gizeli E. (2013) Acoustic detection of DNA conformation in genetic assays combined with PCR. *Sci Rep.* 3:2033.
 71. Dimopoulou DG, Zervou MI, Trachana M, Myrthianou E, Pratsidou-Gertsi P, **Kardassis D**, Garyfallos A, Goulielmos GN. (2013) Investigation of juvenile idiopathic arthritis susceptibility loci: results from a Greek population. *Hum Immunol.* 74(9):1194-8.
 72. Costet P, Ehrenborg E, Fisher R, Fielding B, Groen A, **Kardassis D**, Malle E, Mulder M, Niemeier A, Norata GD, Hansen AT, Eckardstein Av. (2013) European lipoprotein club: report of the 35th ELC annual conference. *Atherosclerosis.* 226(2):510-6.
 73. Fotakis P, Tiniakou I, Kateifides AK, Gkolfinopoulou C, Chroni A, Stratikos E, Zannis VI, **Kardassis D**. (2013) Significance of the hydrophobic residues 225 to 230 of apoA-I for the biogenesis of HDL. *J Lipid Res.* 54(12):3293-302.
 74. Fotakis P, Kateifides A, Gkolfinopoulou C, Georgiadou D, Beck M, Grundler K, Chroni A, Stratikos E, **Kardassis D**, Zannis VI. (2013) Role of the hydrophobic and charged residues in the 218 to 226 region of apoA-I in the biogenesis of HDL. *J Lipid Res.* 2013 Dec;54(12):3281-92.
 75. Fotakis P, Vezeridis A, Dafnis I, Chroni A, **Kardassis D**, Zannis VI. (2014) apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. *J Lipid Res.* 55(7):1310-1323.
 76. Thymiakou E, **Kardassis D**. Novel mechanism of transcriptional repression of the human ATP binding cassette transporter A1 gene in hepatic cells by the winged helix/forkhead box transcription factor A2. *Biochim Biophys Acta.* 1839(6):526-36.
 77. Kardassis D, Mosialou I, Kanaki M, Tiniakou I, Thymiakou E. (2014) Metabolism of HDL and its regulation. *Curr Med Chem.* 21(25):2864-80.
 78. **Kardassis D**, Gafencu A, Zannis VI, Davalos A. (2015) Regulation of HDL genes: transcriptional, posttranscriptional, and posttranslational. *Handb Exp Pharmacol.* 224:113-79.

79. Zannis VI, Fotakis P, Koukos G, **Kardassis D**, Ehnholm C, Jauhiainen M, and Chroni A. (2015) HDL biogenesis, remodeling, and catabolism. *Handb Exp Pharmacol.* 224:53-111.
80. Tiniakou I, Drakos E, Sinatkas V, Van Eck M, Zannis VI, Boumpas D, Verginis P, and **Kardassis D**. High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function. *J Immunol.* 2015 May 15;194(10):4676-87.
81. Fotakis P, Kuivenhoven JA, Dafnis E, **Kardassis D**, and Zannis VI. (2015) The Effect of Natural LCAT Mutations on the Biogenesis of HDL. *Biochemistry.* 54(21):3348-59.
82. Gkouskou KK, Ioannou M, Pavlopoulos GA, Georgila K, Sigano A, Nikolaidis G, Kanellis DC, Moore S, Papadakis KA, **Kardassis D**, Iliopoulos I, McDyer FA, Drakos E, Eliopoulos AG. (2015) Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. *Oncogene.* PMID: 26279300
83. Gkolfinopoulou C, Stratikos E, Theofilatos D, **Kardassis D**, Voulgari PV, Drosos AA, and Chroni A. (2015) Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. *J Rheumatol.* 42(9):1652-60.
84. Tiniakou I, Kanaki Z, Georgopoulos S, Chroni A, Van Eck M, Fotakis P, Zannis VI, and **Kardassis D**. (2015) Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice. *Atherosclerosis.* 243(1):77-85.
85. Stavri S, Simionescu M, **Kardassis D**, and Gafencu AV. (2015) Krüppel-like factor 4 synergizes with CREB to increase the activity of apolipoprotein E gene promoter in macrophages. *Biochem Biophys Res Commun.* 468(1-2):66-72.
86. Roman C, Fuior EV, Trusca VG, **Kardassis D**, Simionescu M, and Gafencu AV. (2015) Thyroid hormones upregulate apolipoprotein E gene expression in astrocytes. *Biochem Biophys Res Commun.* 468(1-2):190-5.
87. Theofilatos D, Anestis A, Hashimoto K, **Kardassis D**. (2016) Transcriptional regulation of the human Liver X Receptor α gene by Hepatocyte Nuclear Factor 4 α . *Biochem Biophys Res Commun.* 469(3):573-9.